About US
Contact us
-
The hits keep coming: Apotex loses 31 drug approvals after FDA cites plants for 'inadequate' controlsIt’s been a troubled few years for Canadian generics maker Apotex after the unsolved murder of founder Barry Sherman and a possible sale in the works. Now, aftermultiple warnings from the FDA, Apotex2019/7/10
-
FDA promises 'elevated' new drug approvals, but warns of potential pitfalls: reportThe FDA has approved 14 new drugs so far this year, lagging behind the 20 approvals it had charted by this time last year. Is it a sign that the FDA is becoming more cautious in the wake of Scott Got2019/7/9
-
Novartis amps up Symjepi launch to fill Pfizer's EpiPen supply gapMylan and its EpiPen manufacturing partner Pfizer have had trouble keeping up with demand. That's not good news as the key back-to-school season nears. Except, perhaps, for Novartis' Sandoz un2019/7/9
-
Bayer floats animal health merger with Lilly spinoff Elanco: reportBayer’s for-sale animal health unit has been stirring up interest among private equity players—but the German pharma may have another buyer in mind. The company has approached Elanco, spun off by Eli2019/7/8
-
J&J fails latest bid to 'cut and run' from Oklahoma opioid trial: AGAfter prosecutors rested their case in the Oklahoma opioid lawsuit, Johnson & Johnson kicked up an argument to toss out the case altogether. The state didn't offer enough evidence to show J&2019/7/8
-
Roche, Merck, Novartis and others hike prices on 83 meds starting in July: analystIt’s not uncommon for drugmakers to raise prices on big-selling meds to start each year and at each year's halfway point. So as the calendar turned to July, many companies marked the occasion with2019/7/5
-
Sanofi, Eisai join Lilly's SCOTUS bid to save Cialis from 'overly broad' patent claimsEli Lilly has a message for the U.S. Supreme Court: We aren’t going to take a $20 million patent loss for Cialis sitting down. Now, Lilly can count on a couple of friends ready to join the fight—and2019/7/5
-
Roche pushes back Spark merger deadline as U.S., U.K. antitrust reviews drag onRoche and Spark Therapeutics’ road to a $4.3 billion merger has been a rocky one, with various delays pushing the long-gestating agreement back four times. Now, in order to get all its regulatory duc2019/7/4
-
NICE shuts down AZ's Tagrisso—and backs Pfizer rival Vizimpro insteadEngland’s cost watchdogs won’t get behind AstraZeneca blockbuster Tagrisso in previously untreated patients with EGFR-mutated lung cancer. But in a change of events, they’re instead backing a Pfizer2019/7/4
-
Merck abandons $7M in grants for long-term IT hiring plan in AustinWhen Merck moseyed into the Lone Star State as part of a global IT restructuring, it pitched a robust hiring plan in exchange for nearly $7 million in tax breaks and grants. Now, after Merck pulled b2019/7/3